Company news
Summit Therapeutics Inc. (NASDAQ:SMMT) news
Summit Therapeutics Inc. news releases on 6ix. Latest, Jan 5, 2023: Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Press releases — page 3
Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023
Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody
December 5, 2022
Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors
November 16, 2022
Summit Therapeutics Inc. Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2022
November 8, 2022
Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
October 19, 2022
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
October 12, 2022
Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors
October 2, 2022
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
August 10, 2022
Summit Therapeutics Closes Fully-Subscribed $100 Million Rights Offering
August 8, 2022
Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President
July 25, 2022
Summit Therapeutics Announces Commencement of $100 Million Rights Offering
July 17, 2022
Summit Therapeutics Provides Update on Ridinilazole
July 13, 2022
Summit Therapeutics Announces $100 Million Rights Offering
June 21, 2022
Summit Therapeutics’ Upcoming Annual Shareholders’ Meeting
June 2, 2022
Summit Therapeutics Appoints Ankur Dhingra as Chief Financial Officer
May 31, 2022
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
May 10, 2022
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021
March 16, 2022
Summit Therapeutics Announces Postponement of Its Planned Rights Offering
February 8, 2022
Summit Therapeutics Announces Rights Offering
January 24, 2022
Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
January 9, 2022
Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
January 4, 2022
Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
December 19, 2021
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021
November 14, 2021
Summit Therapeutics Bolsters Its Board of Directors with Seasoned Regulatory & Clinical Research Executive Dr. Urte Gayko
November 2, 2021
Summit Therapeutics Appoints Prominent Biotech Attorney and Advisor Kenneth A. Clark to Its Board of Directors
October 7, 2021
Summit Therapeutics Presents Further Breakthrough Insights Surrounding the Novel Mechanism of Action for its Investigational Drug Ridinilazole During IDWeek 2021
September 29, 2021
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2021
August 10, 2021
Summit Therapeutics Provides Update on Ri-CoDIFy Trials
August 10, 2021
Summit Therapeutics Presents Breakthrough Research Data from Phase II Studies, including Evidence Validating Microbiome Preservation, for its Investigational Drug Ridinilazole
July 11, 2021
Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePoster
June 30, 2021
Summit Therapeutics set to join Russell 3000® Index
June 7, 2021
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
May 17, 2021
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2021
May 16, 2021
Summit Therapeutics Announces Closing of $75 Million Rights Offering
May 11, 2021
Summit Therapeutics Publishes Scientific Updates to Corporate Website
May 5, 2021
Summit Therapeutics’ Rights Offering Nearing Expiration Date; Robert W. Duggan Declares Intention to Fully Oversubscribe in the Rights Offering
May 4, 2021
Summit Therapeutics Announces Commencement of Rights Offering
April 20, 2021
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2020
March 16, 2021
Summit Therapeutics Appoints Dr. Mahkam (“Maky”) Zanganeh as Chief Operating Officer
November 22, 2020
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2020
November 15, 2020
Summit Announces Closing of Private Placement of $50 Million
November 5, 2020
Summit Announces Agreement For a Fundraising of approximately $50 Million
October 1, 2020
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020
September 28, 2020
Summit Announces Effectiveness of Scheme of Arrangement and Completion of Redomiciliation to Delaware, USA
September 17, 2020
Summit Therapeutics Announces U.K. Court Approval of Scheme
September 16, 2020
Summit Announces Results of Court Meeting and General Meeting
August 18, 2020
Summit Announces Intention to Redomicile its Holding Company to the United States
July 15, 2020
Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health
July 12, 2020
Summit Appoints Michael Donaldson as Chief Financial Officer
June 7, 2020
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020
June 1, 2020